Ratnakar Securities Pvt. Ltd.

KREBS BIOCHEMICALS & INDUSTRIES LTD.

NSE : KREBSBIOBSE : 524518ISIN CODE : INE268B01013Industry : Pharmaceuticals & DrugsHouse : Private

BSE87.291.76 (+2.06 %)

PREV CLOSE ( ) 85.53

OPEN PRICE ( ) 89.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 336

TODAY'S LOW / HIGH ( )86.55 89.00

52 WK LOW / HIGH ( )63.55 129

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 02-12 1991

Management Info

R T Ravi - Chairman Jitendra Shah - Managing Director

Registered Office

Address Kothapalli Village,Anakapalli,Kasimkota Mandal,
Vishakhapatnam,
Andhra Pradesh-531031

Phone 040-66808040 / 9121144984

Email marketing@krebsbiochem.com / com_sec@krebsbiochem.com

Website www.krebsbiochem.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

23Jun Krebs Biochemicals & Industries inform
Krebs Biochemicals & Industries has informed that pursuant to SEBI (..

28May Krebs Biochemicals and Industries info
Pursuant to Regulation 24A of the SEBI (Listing Obligation and Disclosur..

24Mar Krebs Biochemicals & Industries inform
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of..

10Feb Krebs Biochemicals & Industries inform
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, Krebs Bioche..

05Feb Krebs Biochemicals and Industries info
Krebs Biochemicals and Industries has informed that it enclosed copies o..

Financials

in Millions

	QTR Mar 25	ANNUAL 25
Net Profit	-82.68	-269.39
Gross Profit	-82.53	-269.24
Operating Profit	-50.69	-143.21
Net Sales	61	433.12

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 35008.75 (5.62%)	M.Cap ( in Cr)72438.87
Onesource Specialty (BSE) 2194.45 (9.41%)	M.Cap ( in Cr)23415.17
Glaxosmithkline Phar (BSE) 3457.70 (4.86%)	M.Cap ( in Cr)56395.27
Astrazeneca Pharma I (BSE) 8896.30 (1.81%)	M.Cap ( in Cr)22332.50
Neuland Laboratories (BSE) 12118.80 (1.32%)	M.Cap ( in Cr)15375.21

Shareholding Pattern

	PROMOTERS	72.74%
	NON-INSTITUTION	26.76%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

KREBS BIOCHEMICALS & INDUSTRIES LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES